Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Heart and Blood Diseases

Rare Diseases

Carcinoma

Carcinoma, Renal Cell

Atherosclerosis

Vascular Diseases

Urinary Bladder Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urologic Diseases

Male Urogenital Diseases

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Kidney Neoplasms

Kidney Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Immune Checkpoint Inhibitors

Participants on other than ICIs cancer therapies

Arterial Doppler (ultrasound, no radiation, no contrast agent) and blood sampling twice for participants on ICIs

Arterial Doppler for Flow Mediated Reserve measurement

Isabelle Sauret, MBS

Mariana Mirabel, MD, PhD

Immune checkpoint inhibitors (ICIs) are largely prescribed in a growing number of cancer diseases and at earlier stages (non metastatic cancer). Among immune-related adverse events, (iRAEs), the incidence of major cardiovascular events due to atherosclerosis reaches 13% at one year in patients at high risk. To the best of our knowledge, the mechanisms of this acceleration of atherosclerosis have not been studied to this date.

The VICKI study aims at furthering our knowledge on the mechanisms of atherosclerotic plaque instability by means of a prospective single-centre pilot study, by comparing:

* surrogate markers of clinical vasculo-toxicity with arterial Doppler (flow mediated reserve) as defined by the International Cardio-Oncology Society;
* circulating biomarkers

Before and after receiving ICIs for solid cancer treatment.

Context. Immune checkpoint inhibitors (ICIs) are largely prescribed in a growing number of cancer diseases and at earlier stages (non metastatic cancer). Among immune-related adverse events, (iRAEs), the incidence of major cardiovascular events due to atherosclerosis reaches 13% at one year in patients at high risk. To the best of our knowledge, the mechanisms of this acceleration of atherosclerosis have not been studied to this date.

Endothelial dysfunction is a predictor of the development of atherosclerotic plaque and events related to erosion or rupture. Endothelial dysfunction correlates well with the increase of circulating microparticles in various populations. The increase of circulating microparticles is also associated with major cardiovascular events.

The International society of Cardio-Oncology (IC-OS) recently published a definition for subclinical vascular toxicities due to ICIs. It includes non-invasive imaging methods readily available at the bedside (Herrmann et al. European Heart Journal 2022), largely replicated in the recent European Society of Cardiology (ESC) guidelines 2022. It includes the decrease of flow mediated reserve \<7% or hyperhemia index \<2; or the decrease of any of these biomarkers \> 50% from baseline.

Aims and Methods. The VICKI study aims at furthering our knowledge on the mechanisms of atherosclerotic plaque instability by means of a prospective single-centre pilot study, by comparing:

* surrogate markers of clinical vasculo-toxicity with arterial Doppler (flow mediated reserve, hyperhemia index, plaque volume) as defined by IC-OS;
* circulating microparticles; Before and after receiving ICIs for solid cancer treatment.

The number of participants:

* 40 patients receiving ICIs for solid cancer (alone or in combination of other cancer drugs);
* 40 controls (matched by age, gender, cancer type) not treated by ICIs.

Duration of participation: up to 6 weeks. Inclusion period: 12 months.

Perspectives. The VICKI study may improve our understanding of the mechanisms of atherosclerosis mediated major cardiovascular events. If circulating biomarkers correlate well with Doppler surrogate markers of vascular toxicity, larger studies to refine prediction models could be undertaken. This would be a step forward personalized care for the prediction of major cardiovascular events on ICIs.

All participants will undergo the same cardiovascular assessment; only cancer therapies differ according to standard of care.

Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside

Surrogate marker of endothelial dysfunction : Signifiant FMD variation on ICIs as defined by the International Cardio-Oncology Society

Increase in microparticles (CD144+, CD31+/41-, CD62e+, CD235a+, CD41+, CD11+, CD3+); cytokines (e.g., IL-1b, IFNg, TNFa, VEGF-A, C, D, HGF); single-cell profiling and deep immunophenotyping.

Collection of clinically relevant MACE at clinical follow-up: acute coronary syndrome; coronary angioplasty; stroke; cardiac suddent death, myocarditis, myositis.

Institut National de la Santé Et de la Recherche Médicale, France

Institut Mutualiste Montsouris

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside	NCT06020651	Renal Cell Carc... Bladder Cancer MSI-H Cancer Cancer	Arterial Dopple...	18 Years -	Institut Mutualiste Montsouris
Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside	NCT06020651	Renal Cell Carc... Bladder Cancer MSI-H Cancer Cancer	Arterial Dopple...	18 Years -	Institut Mutualiste Montsouris

Spots Global Cancer Trial Database for arterial doppler for flow mediated reserve measurement